10 Obesity Drug Companies to Watch in 2026

Key Takeaways

• Eli Lilly’s retatrutide showed 28% weight loss in Phase III
• Novo Nordisk added oral Wegovy pill and amylin combo CagriSema
• Roche’s CT‑388 achieved 22.5% greater loss vs placebo in Phase II
• Viking Therapeutics’ oral VK2735 cut weight 12.2% in 13 weeks
• Obesity drug market forecast $100‑130 billion by 2035

Pulse Analysis

The obesity epidemic has turned weight‑loss drugs into a strategic growth engine for the pharmaceutical industry. After the blockbuster success of injectable GLP‑1 agents such as semaglutide, investors are eyeing a market projected at $100‑130 billion by 2030‑35. Yet reliance on weekly injections limits patient adherence, prompting a wave of innovation focused on oral delivery, multi‑agonist mechanisms and metabolic comorbidities like type 2 diabetes and MASH.

Companies are racing to differentiate their pipelines. Eli Lilly’s retatrutide, a triple GLP‑1/GIP/glucagon agonist, produced an average 28% body‑weight reduction in an 80‑week Phase III trial, while its oral GLP‑1 Foundayo adds a pill option. Novo Nordisk is leveraging amylin synergy with CagriSema and advancing zenagamtide into Phase III. Mid‑size players such as Viking Therapeutics and Structure Therapeutics are proving that oral GLP‑1 candidates can achieve 12‑16% weight loss in early studies, challenging the injection‑only paradigm.

The broader implications are significant for investors and healthcare systems. A diversified portfolio of oral and multi‑agonist drugs could expand treatment eligibility, improve long‑term adherence, and generate sustained revenue streams across cardiometabolic indications. However, developers must navigate safety signals, pricing pressures, and regulatory scrutiny as the market matures. Stakeholders who monitor trial outcomes and partnership activity will be best positioned to capitalize on the next wave of obesity therapeutics.